The epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies are a valid therapeutic strategy for patients with metastatic colorectal cancer (mCRC).
differentiation, migration, and invasion (1) . The dysregulation of EGFR has been observed in a wide range of cancers (2, 3) and implicated in tumor progression and resistance to radiation-induced cell death (4) .
Enhanced EGFR ligand expression and an autocrine or paracrine EGFR circuit are the main mechanisms in cancer development and progression (5) . The EGFR ligand family is comprised of seven transmembrane precursor proteins whose expression and processing are tightly regulated. These ligands can be classified based on their affinity for EGFR. Epidermal growth factor (EGF), betacellulin (BTC), heparin-binding EGF-like growth factor (HB-EGF), and transforming growth factor-alpha (TGF-α) are high-affinity ligands with binding affinity (K D ) of 0.6 to 9.2 nM, whereas amphiregulin (AREG), epiregulin (EREG), and epigen (EPI) are considered low-affinity ligands with K D of 350 nM to 2.8 μM (6, 7). EGFR ligands exhibit different signaling intensities, durations, and trafficking, resulting in differential EGFR signaling and physiological consequences (8) (9) (10) . AREG and EREG are EGFR ligands that are predominantly expressed in CRC cell lines (11) . mCRC patients with a higher gene expression of EREG and AREG prior to treatment tend to have better disease control by cetuximab than low expressers (12) .
On the other hand, mCRC patients with disease progression have elevated TGF-α (13) .
An increased expression of high-affinity ligands, such as TGF-α and HB-EGF, was also observed in a mouse colorectal cancer (CRC) model with acquired resistance to cetuximab (14) . An elevated level of TGF-α or HB-EGF has been observed in other cancers, including advanced ovarian cancer, breast cancer (15) (16) (17) and lung cancer (18) , and is associated with worse clinical survival. Structural studies of the EGF-EGFR complex depict the process of EGFR activation after ligand binding (19) (20) (21) (22) , which triggers a conformational change in EGFR from a tethered form to an open form. EGFR-targeted antibodies on the market or under development differ in their isotype, binding affinity, and mechanism of EGFR binding, and show different characteristics (23) (24) . Recently, mixtures of antibodies targeting non-overlapping epitopes on EGFR (Sym004 and MM-151) were developed and reported to have enhanced inhibitory activity on EGFR signaling and tumor progression (25) (26) .
In this study, we disclose the novel anti-EGFR antibody GC1118 with a distinct binding epitope and efficacy. The superior inhibitory activity of GC1118 on high-affinity EGFR ligands, to which current clinical antibodies show restricted inhibitory activity, reflects the potential therapeutic advantage of GC1118 in treating cancer patients where high-affinity EGFR ligands are implicated in tumor progression, metastasis, and resistance to current cancer therapeutics.
Materials and Methods

Expression and purification of soluble EGFR and GC1118 Fab
The extracellular domain of EGFR encompassing domains I to IV (sEGFR) was expressed using a baculovirus expression system in Spodoptera frugiperda (Sf9) cells.
After adjusting the pH of the expression media to 7.5, the medium was applied to an NHS-activated HP column (GE Healthcare) coupled with GC1118 IgG. sEGFR was eluted using an elution buffer (20 mM Na-citrate pH 3.0, 100 mM NaCl) after washing the column with a wash buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl). The eluted sEGFR was applied to a HiLoad 16/600 Superdex200 PG column (GE Healthcare) for size exclusion chromatography (SEC) purification with the SEC buffer (20 mM Tris-HCl pH7.5, 100 mM NaCl).
The Fab fragment of GC1118 was generated by digestion with a papain. GC1118 was incubated with a papain (1:50 w/w) in 1 mM DTT at 37°C for 1 h and the reaction was stopped with 20 mM iodoacetamide. To remove the Fc fragment, papain-treated solution was mixed with a Protein A resin for 1 h at 4°C. A flow-through including Fab proteins was collected. These fractions were further purified by a gel filtration (HiLoad 16/600 Superdex200 PG column, GE Healthcare) and confirmed with a SDS-PAGE.
The purified sEGFR and the Fab fragment of GC1118 were mixed at a 1:2 molar ratio and incubated for 1 h at 4°C. The sEGFR/GC1118 Fab fragment complex was purified using a HiLoad 16/600 Superdex200 PG column with the SEC buffer. The complex was confirmed by SDS-PAGE and concentrated to 15 mg/ml for crystallization.
Crystallization, data collection and structure determination
Optimized crystallization condition for sEGFR/GC1118 complex was 0.1 M ammonium sulfate, 0.1 M Na-acetate (pH 4.6) and 25% PEG4000. In the initial crystallization screening of the sEGFR/GC1118 complex, a microbatch method was used with commercial crystal screening kits (Hampton Research). Equal volumes of sEGFR/GC1118 solution and crystallization buffer were mixed in microbatch plates and incubated for 1 week at 13°C.
For cryo protection, 15% ethylene glycol was added to the reservoir buffer before the X-ray diffraction experiments. Data was harvested by using the Spring-8 beamline BL26B1. The X-ray diffraction data of the sEGFR/GC1118 complex was processed with HKL2000 (27) . The sEGFR/GC1118 complex structure was determined by the molecular replacement method (MR) with Molrep in CCP4 suite using the sEGFR structure and Fab structure respectively from sEGFR/cetuximab complex structure (PDB ID: 1YY9) as a search model (28, 29) . First, the sEGFR structure was used for MR. The found solution structure for sEGFR was fixed and then the Fab structure of cetuximab was used for second round MR. One sEGFR/GC1118 Fab complex was found in asymmetry unit. Coot and Refmac5 were used for model building and refinement (30, 31) . ArealMol and Sc program in CCP4 package were used to calculate buried surface area (BSA) and shape complementarity coefficient (Sc) (29) . The Pymol program was used for figure drawing and superposition of the complex structures of GC1118, cetuximab and matuzumab. The statics of the data collection and refinement are shown in Supplementary Table S1 . The sEGFR/GC1118 complex structure is deposited in PDB (PDB ID: 4UV7).
Cell lines
CRC cell lines (C2bbe1, HCT8, HCT15, LS174T, and Lovo) were obtained from 
Antibodies and reagents
Anti-pEGFR, anti-EGFR, anti-pERK, anti-ERK, anti-pAkt, and anti-Akt were purchased from Cell Signaling. HB-EGF, TGF-α, BTC, EREG, and AREG were purchased from R&D systems. EGF was purchased from BD Biosciences. Horseradish peroxidaseconjugated anti-mouse and anti-rabbit antibodies were purchased from Invitrogen.
Cetuximab (Erbitux) was from Merck.
Flow cytometry-based EGFR binding analysis
CRC cells were pre-incubated with cetuximab (Merck) or GC1118 for 2 h at 4°C and treated with various concentrations of ligands for 10 min at 37°C. After two washes with FACS buffer, the cells were incubated with 0.5 μg/ml of goat anti-human IgG-PE (Sigma) for 30 min at 4°C, washed twice with FACS buffer, and analyzed using a FACSCalibur. The final analysis and graphical output were generated using FlowJo (TreeStar) and GraphPad Prism 5.01 (GraphPad Software, San Diego, CA, USA).
Immunoblotting
The cells were lysed using cell lysis buffer (Cell Signaling) containing a protease and phosphatase inhibitor cocktail (Pierce), and clarified by centrifugation. The cell lysates (20 μg per lane) were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and transferred to nitrocellulose membranes. After incubation with protein-free T20 blocking buffer (Pierce) for 1 h, the membranes were incubated with primary antibody (1:2,000) overnight at 4°C and then incubated with 1:20,000 
Ligand-induced proliferation and inhibition assay
Cell proliferation was measured using the CellTiter 96 Aqueous One solution Reagent (Promega) according to the manufacturer's instructions. The cells were plated into 96-well plates at a density of 2,500 -7,000 cells per well and grown in DMEM or RPMI with 10% FBS. After 18 h, the medium was completely changed to serum-free medium, followed by the addition of the antibody and EGFR ligands, and incubated for three days.
MTS solution was added, and the proliferation level was determined using a microplate reader (Versamax, Molecular Devices). 
Tumor xenograft mouse model
Results
The complex structure of the extracellular domain of EGFR and GC1118
GC1118 is a fully human antibody whose generation and affinity maturation process from the original mouse anti-EGFR antibody A13 was published previously (32, 33) . To analyze the binding mode and predict the inactivation mechanism of EGFR upon GC1118 binding, we determined a sEGFR-GC1118 Fab complex structure, using X-ray crystallography. A sEGFR-GC1118 Fab complex was purified by size exclusion chromatography (SEC) and diffracted at 1.9 A˚ resolutions. A molecular replacement (MR) was applied to solve the complex structure of the sEGFR-GC1118 Fab by using reported structures of tethered sEGFR-cetuximab Fab complex. A refined sEGFR- III, those of matuzumab and GC1118 are on the linear discrete sequences (Fig. 1C) (34, 35) . GC1118 and matuzumab recognize the loop (from R353 to H359) located in the Nterminus and a short loop (from K454 to T464) in the C-terminus of domain III, respectively (Fig. 1C) (34, 35) . While the binding epitopes of cetuximab and GC1118 overlap with the EGF-binding sites, the epitope of matuzumab is located far from the EGF-binding site (21, 34, 35) . Matuzumab does not inhibit EGF binding to EGFR but prevents the conformational change required for dimerization (35) . Our data and previous reports support the conclusion that both GC1118 and cetuximab maintain EGFR in the tethered conformation and block EGF binding to EGFR and subsequent EGFR dimerization (34) .
Comparison of the EGFR-binding sites of EGF, cetuximab, and GC1118
The crystal structure of EGF and its receptor revealed that EGF interacts with EGFR through three interfaces, one site on domain I and two sites on domain III of EGFR, namely site 2 and site 3 ( Fig. 2A) (21) . Site 2 encompasses residues 350-357 and has two important interactions: a hydrophobic interaction formed between the aromatic residue of EGF Y13 and EGFR F357, and a salt bridge between EGF R41 (100% conserved throughout the ligands) and EGFR D355 (Fig. 2A) . These two interactions involving R41 and Y13 of EGF were found to be critical determinants for receptor binding (21, 36, 37) . Site 3 has two distinct interactions, a hydrophobic and hydrophilic interaction. The hydrophobic pocket consisting of L382, F412, and I438 in EGFR forms an interaction with EGF L47, and several residues on the receptor, such as Q384 and K465, form a hydrogen bond with the ligand (21). The binding epitopes of GC1118 and cetuximab overlap with the EGF-binding site on domain III (Fig. 2 ). GC1118's epitope primarily resides on site 2 encompassing residues 350-357, whereas cetuximab's epitopes are dispersed on site 3 including Q384-N473 (Fig. 1B, Fig. 2B and 2C ). The epitopes of GC1118 (R353-H359) fully overlap with site 2, which is the critical binding site of EGF to EGFR. The interaction between GC1118 Y59 (on HCDR2 of GC1118) and EGFR D355 would block a salt bridge between EGF R41 and EGFR D355, one of the critical sites for the EGF-EGFR interaction. Additionally, H99 on HCDR3 and W99 and W101 on the LCDR3 of GC1118 thoroughly hinder the hydrophobic interaction between EGFR F357 and EGF Y13. On the other hand, the binding epitopes of cetuximab are largely superimposed with site 3.
Y102 on the HCDR3 of cetuximab protrudes into the hydrophobic pocket of site 3, where EGF L47 (L48 in TGF-α) interacts with EGFR Q384 and EGFR Q408 through hydrogen bonds (34, 38) .
GC1118 efficiently blocks the binding of high-as well as low-affinity ligands to EGFR
GC1118 has binding affinity of 0.16 nM (K D ) to EGFR, compared with cetuximab, which has a K D of 4.5 nM (Supplementary Fig. S1 , Table S2 ). Different binding affinities and binding modes of GC1118 could lead to differential effects on ligand competition for EGFR. To test this hypothesis, GC1118 was labeled with a fluorescent dye, and the level of EGFR-bound GC1118 in cancer cells was measured using flow cytometry.
Increasing concentrations of EGFR ligands were introduced to determine the binding (Fig. 3) . Even 136-to 277-fold excess molar ratios of low-affinity ligands (1 μg/ml of AREG and EREG is 91 nM and 185 nM, respectively) could displace neither GC1118 nor cetuximab from EGFR (Fig. 3, Supplementary Fig.   S2 ), indicating that low-affinity ligands are well blocked from binding to EGFR by these two antibodies. The fraction of EGFR-bound cetuximab decreased as the concentration of high-affinity ligands increased, while GC1118 maintained its binding status to EGFR in the presence of up to 32-to 125-fold excess amounts of high-affinity ligands (0.5 μg/ml of HB-EGF, BTC, EGF, and TGF-α are 21.7 nM, 33.3 nM, 83.3 nM, and 83.3 nM, respectively; Fig. 3, Supplementary Fig. S2 ). Among the high-affinity ligands, cetuximab appeared to be easily displaced by HB-EGF, in which 20% and 40-60% of cetuximab was detached from EGFR with a 1.3-and 32-fold excess molar ratio of HB-EGF, 
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respectively. These results indicate that GC1118 potently blocks the interaction of EGFR with a broad range of ligands.
GC1118 exhibits a potent inhibition on high-affinity EGFR ligand-induced signaling and proliferation
The binding of EGF ligands to EGFR activates the tyrosine kinase activity of the receptor (2). Tyrosine 1068 (Y1068) of EGFR is one of the major phosphorylation sites that allow Grb2 binding and activation of the MAPK signaling pathway (39) . To determine the inhibitory activities of GC1118 on EGFR signaling, CRC cells were induced with EGFR ligands in the presence or absence of GC1118 or cetuximab, and the phosphorylation status of key EGFR signaling molecules was evaluated (Fig. 4A ).
GC1118 completely inhibited the high-affinity EGFR ligand-induced Y1068 phosphorylation of EGFR starting from 0.1 μg/ml, whereas a complete inhibition was observed only at 50 μg/ml of cetuximab (Fig. 4A) . For HB-EGF-induced Y1068 phosphorylation, up to 50 μg/ml of cetuximab showed no inhibition. Both antibodies efficiently blocked the low-affinity EGFR ligand (EREG, AREG)-induced Y1068 phosphorylation in a dose-dependent manner (Fig. 4A) . A potent inhibitory effect of GC1118 on high-affinity EGFR ligand-induced signaling was more pronounced for the EGFR downstream signaling molecules, including Akt and Erk (Fig. 4A) .
To evaluate the inhibitory activity of GC1118 on EGFR ligand-induced proliferation, HCT8 cell line was treated with EGFR ligands in the presence of antibodies. GC1118 was capable of potently inhibiting both high-and low-affinity EGFR ligand-driven cell proliferation, whereas the inhibitory activities of cetuximab were restricted to only lowaffinity EGFR ligand-driven cell proliferation (Fig. 4B ).
EREG and AREG are predominant EGFR ligands expressed in CRC and only a small fraction of high-affinity ligands are expressed (12) . To simulate the impact of highaffinity ligands on antibody efficacy in CRC patients, the HCT8 cell line was treated with increasing concentrations of HB-EGF, and the inhibitory activities of the antibodies on cell growth were evaluated. Both antibodies efficiently inhibited AREG-induced proliferation with an EC 50 of 0.01 μg/ml (0.067 nM); however, as the concentration of HB-EGF increased (molar ratio of AREG: HB-EGF=98:2 and 90:10), the inhibitory activity of cetuximab on proliferation reduced gradually and finally disappeared (Fig. 4C) .
Even a small fraction of HB-EGF (10% in the total ligand pool) completely blocked the inhibitory activity of cetuximab. On the other hand, GC1118 maintained its inhibitory activity, although it decreased slightly, with an EC 50 of 0.27 μg/ml and 8.68 μg/ml in the presence of HB-EGF at a molar ratio of 2% and 10%, respectively (Fig. 4C) .
GC1118 shows superior antitumor activity in colorectal cancer cells secreting a high level of high-affinity EGFR ligands
To investigate a link between the superior inhibitory effect of GC1118 and the expression of EGFR ligands, we examined the in vitro and in vivo EGFR ligand expression profiles of various CRC cell lines: LS174T, HCT15, LoVo, HCT8, LS513, and SW48. AREG and EREG are the predominant EGFR ligands expressed in these cells as reported by others when cultured in vitro (Fig. 5A) (11) . GC1118 and cetuximab (Fig. 5B) . The LS513 and SW48 tumors maintained their ligand expression pattern exhibited when cultured in vitro, where AREG and EREG were the predominant EGFR ligands (Fig. 5B ).
To test antitumor efficacy, mice with tumors of 200 mm 3 were randomly assigned and treated with each antibody twice a week. The GC1118-treated group showed significant tumor progression retardation compared with the cetuximab-treated group in LS174T, HCT15, HCT8, and LoVo xenograft models, which predominantly expressed highaffinity ligands (Fig. 5C ). In contrast, both GC1118 and cetuximab effectively suppressed the tumor growth of LS513 and SW48 xenografts, which show a relatively low expression of high-affinity ligands (Fig. 5B, 5C ). These results support the conclusion that cetuximab has limited inhibitory activity on tumor xenografts with an elevated level of high-affinity ligand expression. On the other hand, GC1118 has potent antitumor efficacy in CRC xenografts regardless of the EGFR ligands and may show efficacy on a broader CRC patient pool compared with cetuximab. The observed broad range of inhibition could be simply due to the higher binding affinity of GC1118 to EGFR compared with cetuximab. To eliminate this possibility, we compared the inhibitory effect of GC1118 with panitumumab (K D =0.05 nM), which was reported to have a one log higher binding affinity compared with cetuximab but with a binding epitope similar to cetuximab (40) . The weak inhibitory activity of panitumumab towards the high-affinity ligands was more pronounced in the EGFR-signaling downstream effectors such as Erk and Akt (Fig. 4A, Fig. 6A ). Panitumumab at a dose of 50 μg/ml inhibited HB-EGF-, BTC-, TGF-α-, and EGF-induced phosphorylation of EGFR but not of Erk and Akt (Fig. 6A ). This result indicates that panitumumab failed to completely inhibit EGFR signaling (Fig. 6A) . A similar trend of inhibition was also observed in EGFR ligand-driven cell proliferation, where the inhibitory activities of panitumumab were restricted to only low-affinity EGFR ligands (Fig. 6B ).
Discussion
In this study, we report a novel anti-EGFR antibody, GC1118, which exhibits a different binding affinity, binding epitope, and ligand competitive activity from other EGFR antibodies. While cetuximab and panitumumab showed inhibitory activities that were limited to low-affinity ligands, GC1118 showed a potent inhibition of a broad range of ligands, ligand-induced EGFR signaling, and proliferation (Fig. 4, 5, and 6 ). in various cancers (15) (16) (17) (18) and in the lack of response or acquired resistance to cetuximab (13, 14) , our results indicate that GC1118 may have a broad cancer patient pool including those patients progressed after treatment with current EGFR-targeted therapeutics. Based on these promising preclinical results, a phase I clinical trial is under study (ClinicalTrials.gov.Identifier: NCT02352571).
The superior inhibitory activity of GC1118 against high-affinity EGFR ligands appears to arise from a unique binding epitope as well as a high EGFR-binding affinity. M, was displaced from EGFR by excess amounts of high-affinity ligands (Fig. 3 ) and failed to inhibit high-affinity ligandinduced signaling. Panitumumab, with a presumably higher binding affinity than cetuximab, also showed a limited suppressive effect on high-affinity ligands (Fig. 6) .
Panitumumab was reported to have the highest binding affinity to EGFR among the marketed EGFR antibodies (40) and appears to have a higher or comparable binding affinity to GC1118. Overall, these results strongly suggest that the binding epitope is one of the major factors leading to unique ligand inhibitory activities of GC1118.
The crystal structure of the Fab fragment of GC1118 in complex with sEGFR identified a tethered structure of EGFR. This finding indicates that the binding of GC1118 to EGFR blocks the binding of other ligands and keep EGFR in a tethered form. Both GC1118 and cetuximab bind to domain III of EGFR, but their binding regions are quite different. The binding epitope of GC1118 is located in a discrete area that mostly covers R353-H359, including D355 and F357, which are critical for EGF binding.
The binding epitopes of cetuximab are widely dispersed and mostly overlap with Q384-S468 of the EGF-binding sites (34) . According to a mutation analysis, a mutation at 
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D355/F357 did not disturb the binding intensity of cetuximab toward EGFR as much as it did on the EGF-EGFR interaction, suggesting that the interactions with D355, F357, and Q384 are not the major contributors for the cetuximab-EGFR interaction (34) . The critical residues of EGFR for EGF binding were reported to be D355 and F357 interacting with EGF R41 and EGF Y13, respectively, and the residues that constitute the hydrophobic pocket (L382, I438, F412) accommodating EGF L47 (37) . Because a drastic decrease of the binding affinity of EGF to EGFR was observed by mutations at site 2 compared to site 3, it is conceivable that targeting site 2 would be more efficient in blocking the EGF-EGFR interaction. The binding sites of panitumumab are adjacent to and partially overlap with those of cetuximab, which are located mostly on the Cterminal regions of domain III, and this situation might explain the similar inhibitory pattern of panitumumab to cetuximab (41) .
The superior inhibitory effect of GC1118 on high-affinity EGFR ligands forecasts therapeutic implications of GC1118 for a broader range of cancer patients than other current EGFR therapeutics. Gene expression analysis from a clinical study suggests that cetuximab has limited disease control in CRC patients with elevated levels of TGF-α, which accounts for approximately one-third of the CRC patients tested (13) . It is plausible that those patients having higher expression of TGF-α and not responding to cetuximab would benefit from GC1118. EGFR and high-affinity EGFR ligands have been implicated in the generation and activation of tumor vasculature (42) (43) (44) .
Therefore, we expect that the tumor inhibitory activities of GC1118 are not restricted to tumor proliferation only but also extend to influence the crosstalk of tumors with stromal factors leading to migration and invasion. A, HCT8 cells were serum starved for 18 h, treated with 0.1 to 50 μg/ml GC1118 or cetuximab for 2 h, and stimulated with EGFR ligands (EGF, HB-EGF, BTC, and TGF-α, 250 ng/ml; AREG, 300 ng/ml; EREG, 500 ng/ml). pEGFR, pAKT, pERK, EGFR, AKT and ERK expression levels were analyzed by western blotting. B, HCT8 cells were serum starved for 18 h, treated with ligands (EGF and HB-EGF, 50 ng/ml; BTC, 100 ng/ml; TGF-α, 200 ng/ml; AREG and EREG, 300 ng/ml) and various amounts of GC1118 or cetuximab (0.005-100 μg/ml in high-affinity ligand-induced proliferation, 5 pg/ml-10 μg/ml in low-affinity ligand-induced proliferation) for three days. Cell proliferation was analyzed using an MTS assay. Red lines represent GC1118-treated cells and blue lines indicate cetuximab-treated cells. C, HCT8 cells were serum starved for 18 h, treated with various ratios of ligands and 25 pg/ml to 50 μg/ml of GC1118 or cetuximab for three days. Cell proliferation was analyzed using an MTS assay. AREG A, HCT8 cells were serum starved for 18 h, treated with 0.1 to 50 μg/ml GC1118 or panitumumab for 2 h, and stimulated with EGFR ligands (EGF, HB-EGF, BTC, and TGF-α, 250 ng/ml; AREG, 300 ng/ml; EREG, 500 ng/ml). pEGFR, pAKT, pERK, EGFR, AKT or ERK expression levels were analyzed by western blotting. ng/ml; BTC, 100 ng/ml; TGF-α, 200 ng/ml; AREG and EREG, 300 ng/ml) and various amounts of GC1118 or panitumumab (0.005-100 μg/ml in high-affinity ligand-induced proliferation, 5 pg/ml-10 μg/ml in low-affinity ligand-induced proliferation) for three days. 
